+86-28-82633987
ISO ISO
ISO 17025 ISO 17025
usp usp
EN
CN EN

Saikosaponin C

BP1241
20736-08-7
98%
Phytopurify
Bupleuri Radix
Saikosaponin C exhibits anti-HBV activity, it has the potential for therapeutic angiogenesis but is not suitable for cancer therapy, it also might be a novel therapeutic tool for treating human AD and other neurodegenerative diseases. It inhibited caspase-3 activation and caspase-3-mediated-FAK degradation, induced matrix metalloproteinase-2 (MMP-2)、vascular endothelial growth factor (VEGF) 、the p42/p44 mitogen-activated protein kinase (MAPK, ERK). Saikosaponin C is a member of the class of saikosaponins that is saikogenin E substituted by a 6-deoxy-alpha-L-mannopyranosyl-(14)-[beta-D-glucopyranosyl-(16)]-beta-D-glucopyranosyl group at position 3beta. It is a natural product isolated from the traditional Chinese herb, Radix Bupleuri and exhibits anti-HBV replication activity. It has a role as an anti-HBV agent and a plant metabolite.
Catalog No Package Original Price Price Inventory Quantity Operating
BP1241-20mg 20mg
BP1241-100mg 100mg
Chengdu Biopurify Phytochemicals Ltd.
Chengdu Biopurify Phytochemicals Ltd.

Related targets

MAOA SLC6A4 HTR1A CREB1 BDNF
NOS3 TNF NFKB1 IL6 TGFB1 ACTA2 VEGFA COL1A1
MMP2 CLDN1 CD81
NOS3 MAPK1 PIK3CA AKT1 VEGFA KDR
IL6 COL1A1 TIMP1

Product drug property prediction parameters

  • 266.9100

  • 2.9002

  • 2.9005

  • .0287

  • .6076

  • 1.1105

  • Low

  • 73.1988

  • 7.6034

  • No

  • No

  • No

  • No

  • No

  • No

  • 0.0

  • Yes

  • No

  • Yes

  • Yes